PriceTargets.com logo

Celyad Oncology - CYAD Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.60 As of 10/25/2023 01:00 AM ET
+0 (0.00%)
Get New Celyad Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CYAD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CYAD

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Celyad Oncology in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.60.

This chart shows the closing price for CYAD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 polled investment analysts is to n/a stock in Celyad Oncology. This rating has held steady since October 2023, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/12/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
9/10/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/9/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/8/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/6/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/4/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/3/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/3/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
10/13/2022William BlairDowngradeOutperform ➝ Market Perform
2/28/2022HC WainwrightDowngradeBuy ➝ Neutral$2.78
1/11/2022Wells Fargo & CompanyLower TargetOverweight$20.00 ➝ $11.00
12/22/2021UBS GroupDowngradeNeutral ➝ Sell
12/10/2021HC WainwrightLower TargetBuy ➝ Buy$15.00 ➝ $13.00
8/20/2021JonestradingReiterated RatingHold
8/6/2021HC WainwrightLower TargetBuy$17.00 ➝ $15.00
5/10/2021HC WainwrightLower TargetBuy$18.00 ➝ $17.00
3/31/2021JonestradingReiterated RatingBuy ➝ Hold
3/25/2021JonestradingDowngradeBuy ➝ Hold
12/8/2020HC WainwrightLower TargetBuy$22.00 ➝ $18.00
9/29/2020William BlairReiterated RatingBuy
6/1/2020William BlairReiterated RatingBuy
5/7/2020HC WainwrightReiterated RatingBuy
3/26/2020Wells Fargo & CompanyLower TargetOverweight$44.00 ➝ $20.00
3/25/2020HC WainwrightLower TargetIn-Line ➝ Buy$43.00 ➝ $37.00
12/11/2019HC WainwrightReiterated RatingBuy$43.00
(Data available from 12/3/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/7/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/6/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/6/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/5/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/4/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/4/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/3/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/3/2024

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Celyad Oncology logo
Celyad Oncology SA is a clinical-stage biotechnology company, which focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. It operates through the following segments: Cardiology and Immuno-Oncology. The Cardiology segment includes the company's Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-Oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
Read More

Today's Range

Now: $0.60
Low: $0.40
High: $0.65

50 Day Range

MA: $0.67
Low: $0.59
High: $0.85

52 Week Range

Now: $0.60
Low: $0.46
High: $3.07

Volume

3,009 shs

Average Volume

N/A

Market Capitalization

$15.91 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Celyad Oncology?

The following Wall Street sell-side analysts have issued stock ratings on Celyad Oncology in the last year:
View the latest analyst ratings for CYAD.

What is the current price target for Celyad Oncology?

0 Wall Street analysts have set twelve-month price targets for Celyad Oncology in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Celyad Oncology in the next year.
View the latest price targets for CYAD.

What is the current consensus analyst rating for Celyad Oncology?

Celyad Oncology currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CYAD.

What other companies compete with Celyad Oncology?

Other companies that are similar to Celyad Oncology include Fortress Biotech, Iterum Therapeutics, Aileron Therapeutics, Cellectar Biosciences and Spero Therapeutics. Learn More about companies similar to Celyad Oncology.

How do I contact Celyad Oncology's investor relations team?

Celyad Oncology's physical mailing address is RUE EDOUARD BELIN 12, MONT-SAINT-GUIBERT C9, 1435. The company's listed phone number is (210) 039-4100 and its investor relations email address is [email protected]. The official website for Celyad Oncology is www.celyad.com. Learn More about contacing Celyad Oncology investor relations.